CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

BioArctic Partner Eisai Launches Leqembi Pen in Japan

By Public Technologies
  • BioArctic's partner Eisai launched Leqembi Pen in Japan for early Alzheimer's disease on November 13, 2026.
  • Japan is the second launch market following the US; the treatment is now included in Japan's national health insurance drug price list.
  • Japanese approval came on September 16, 2026, making it the country's first anti-amyloid treatment available for home administration.
  • The autoinjector delivers a weekly 500 mg dose using two pens, offering an alternative to intravenous treatment every two weeks.
  • BioArctic receives royalties on global sales and sales milestone payments, with no lecanemab development costs for Alzheimer's disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk